Bausch + Lomb’s Lumify Receives the US FDA’s Approval to Treat Ocular Redness
Shots:
- Bausch + Lomb has received the US FDA’s approval for Lumify Preservative Free eye drops to treat ocular redness due to minor eye irritations
- The studies demonstrated low incidence of side effects such as rebound redness and loss of efficacy over time with Lumify Preservative Free eye drops. The company plans its availability in early 2025 as single-use vials
- Lumify is a free preservative eye drop that contains OTC brimonidine tartrate’s low dose 0.025% for treating ocular redness
Ref: Bausch + Lomb | Image: Bausch + Lomb
Related News:- Bausch + Lomb Reports the US Commercial Availability of Miebo (perfluorohexyloctane ophthalmic solution) for Dry Eye Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
